Development of long-acting recombinant glycoprotein hormones by increasing the carbohydrate content

Research output: Contribution to journalReview articlepeer-review

Abstract

Therapeutic recombinant glycoproteins are important for both the biotechnological industry and clinical purposes. Given the rapid clearance of these proteins from the circulation, they have to be injected frequently to obtain optimal therapy. Several strategies have been developed to overcome this limitation, aiming to increase the half-life of such proteins in the circulation. These strategies included chemical attachment of polyethylene glycol, nanocapsulation, fusion to immunoglobulins or to albumin as protein carriers, or enrichment of the carbohydrate content. Here, we describe a strategy for increasing the half-life of recombinant proteins using gene fusion to increase the carbohydrate content of the protein backbone.

Original languageEnglish
Pages (from-to)1017-1022
Number of pages6
JournalDrug Discovery Today
Volume24
Issue number4
DOIs
StatePublished - Apr 2019

Bibliographical note

Publisher Copyright:
© 2019 Elsevier Ltd

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Development of long-acting recombinant glycoprotein hormones by increasing the carbohydrate content'. Together they form a unique fingerprint.

Cite this